rare
0
Challenges in Conducting Economic Evaluations for Orphan Drugs in Rare Diseases – Healthcare Economist
0

Why is it so difficult to estimate the value of orphan drugs indicated for the treatment of rare diseases? There are a ...

0
Health gains from rare disease, specialty and expedited review drugs – Healthcare Economist
0

James Chambers has produced a series of articles analyzing the health benefits (and cost-effectiveness) using the Tufts ...

Tools4BLS
Logo
Register New Account
Compare items
  • Total (0)
Compare
0
Shopping cart